WestRock Company was announced by MeadWestvaco Corporation and Rock-Tenn Company as the chosen name for the new venture when the two packaging companies complete their previously announced combination.
Hovione today announced a co-promotion and collaboration agreement with Ligand to provide Hovione's customers efficient access to Captisol technology.
DFH Pharma, Inc., a privately held pharmaceutical company focused on the development of HIV therapeutics, announced that it has entered into a Research and Product Development Agreement with Hetero Group ("HETERO"), a privately held research-based global pharmaceutical group with headquarters in Hyderabad, Andhra Pradesh, India, to develop the next generation of HIV maturation inhibitor drugs.
Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Karbinal™ ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up.
Bristol-Myers Squibb has awarded grants totaling $175,000 to the American Cancer Society Eastern Division and Princeton HealthCare System (PHCS) to support comprehensive navigation services for patients with cancer both independently and as part of a collaborative effort among several hospitals in central New Jersey.
The Scripps Research Institute (TSRI) and the Takeda Pharmaceutical Company have announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases.
The new agreement extends an initial collaboration launched in 2010 between scientists on the Florida campus of TSRI and Envoy Therapeutics that led to several breakthroughs in identifying potential new compounds for neurological and psychiatric diseases. Envoy was acquired by Takeda Pharmaceuticals last November.
The next generation of advanced pharmaceutical technologies could be poised to fuel remarkable growth in the $60 billion global drug delivery market, and Rainbow Biosciences—the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC)—plans to be right in the middle of the action.
HUYA Bioscience International announced today a collaborative partnership with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. and Shanghai Pharma Engine Co. Ltd. (collectively, "Zhangjiang Biotech Pharmaceutical Base"). HUYA is an international leader in accelerating the global development of China's pharmaceutical innovations. This new partnership will focus on innovations coming out of companies located in Zhangjiang Biotech Pharmaceutical Base that could meet critical global pharmaceutical pipeline needs.
Cylene Pharmaceuticals, Inc. announced today that it has entered into an exclusive, worldwide Option and License Agreement that will allow TetraGene LLC to advance the development of Quarfloxin and Cylene's associated anticancer quadruplex-targeting technologies. Cylene will receive an upfront fee, as well as potential milestone payments and royalties on product sales for the exclusive license.
Array BioPharma Inc. and Global Blood Therapeutics today announced a multi-target drug discovery collaboration agreement to identify small molecule lead compounds targeting chronic blood-based diseases. Array will develop assays and screen its proprietary lead generation library of 300,000 small molecules to identify both active site and allosteric modulators of certain Global Blood targets. Array's library will allow for rapid hit confirmation and subsequent lead optimization.